New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis: Only PROMises?

Current Opinion in Pulmonary Medicine

Volumn 22, Issue 5, 2016, Pages 434-441

  Wijsenbeek, Marlies ^a   Manena, Mirjam Van ^a   Bonella, Francesco ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RUHRLANDKLINIK   (Germany)

Author keywords

Health related quality of life; idiopathic pulmonary fibrosis; patient reported outcome measures

Indexed keywords

CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; FATALITY; FIBROSING ALVEOLITIS; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HUMAN; KING BRIEF INTERSTITIAL LUNG DISEASE HEALTH STATUS QUESTIONNAIRE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; TOOL TO ASSESS QUALITY OF LIFE IN IPF; IDIOPATHIC PULMONARY FIBROSIS; PATIENT PARTICIPATION; PATIENT-REPORTED OUTCOME;

CLINICAL TRIALS AS TOPIC; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PATIENT PARTICIPATION; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE;

EID: 84975463387     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000294     Document Type: Review

References (63)

1. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015; 192:e3-e19.
2. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071-2082.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083-2092.
4. Russell AM, Ripamonti E, Vancheri C. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment. BMC Pulm Med 2016; 16:10.
5. Overgaard D, Kaldan G, Marsaa K, et al. The lived experience with idiopathic pulmonary fibrosis: a qualitative study. Eur Respir J 2016; 47:1472-1480.
6. Yount SE, Beaumont JL, Chen SY, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. Lung 2016; 194:227-234.
7. The Voice of the Patient; A series of reports from the U.S. Food and Drug Administration's (FDA's) Patient-Focused Drug Development Initiative. March 2015.
8. Swigris JJ, Fairclough D. Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest 2012; 142:291-297.
9. Garibaldi BT, Danoff SK. Symptom-based management of the idiopathic interstitial pneumonia. Respirology 2015. [Epub ahead of print]
10. Bajwah S, Higginson IJ, Ross JR, et al. The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals. Palliat Med 2013; 27:869-876.
11. Bonella F, Wijsenbeek M, Molina-Molina M, et al. European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers. Eur Respir J 2016; 47:597-606.
12. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry, Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. December 2009. http://www.fda.gov/downloads/Drugs/./Guidances/UCM193282.pdf. [Accessed 2 May 2016].
13. Black N. Patient reported outcome measures could help transform healthcare. BMJ 2013; 346:f167.
14. Chen J, Ou L, Hollis SJ. A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res 2013; 13:211.
15. Nelson EC, Eftimovska E, Lind C, et al. Patient reported outcome measures in practice. BMJ 2015; 350:g7818.
16. Santana MJ, Feeny D. Framework to assess the effects of using patientreported outcome measures in chronic care management. Qual Life Res 2014; 23:1505-1513.
17. Ahles TA, Wasson JH, Seville JL, et al. A controlled trial of methods for managing pain in primary care patients with or without co-occurring psychosocial problems. Ann Fam Med 2006; 4:341-350.
18. Wicks P. Commentary: Measuring what matters: the case for patient generated PROMS. BMJ 2015; 350:h54.
19. Britten N, Pope C, Halford S, Richeldi L. What if we made stratified medicine work for patients Lancet Respir Med 2016; 4:8-10.
20. Howell D, Molloy S, Wilkinson K, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol 2015; 26:1846-1858.
21. Fehnel S, DeMuro C, McLeod L, et al. US FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Rev Pharmacoecon Outcomes Res 2013; 13:441-446.
22. Acaster S, Tricia C, Andrew L. Patient CenteredOutcomes Research Institute (PCORI). Development of a Methodological Standard Report: Topic # 3,The Design and Selecton of Patient-Reported Outcomes Measures (PROMs) For Use In Patient Centered Outcomes Research. 2012.
23. Sampson C, Gill BH, Harrison NK, et al. The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study. BMC Pulm Med 2015; 15:155.
24. Concannon TW. Can patient centered outcomes research improve healthcare BMJ 2015; 351:h3859.
25. Saketkoo LA, Mittoo S, Frankel S, et al. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. J Rheumatol 2014; 41:792-798.
26. Russell AM, Sprangers MA, Wibberley S, et al. The need for patient-centred clinical research in idiopathic pulmonary fibrosis. BMC Med 2015; 13:240.
27. Greenhalgh J, Abhyankar P, McCluskey S, et al. How do doctors refer to patient-reported outcome measures (PROMS) in oncology consultations Qual Life Res 2013; 22:939-950.
28. Swigris JJ, Esser D, Conoscenti CS, Brown KK. The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes 2014; 12:124.
29. Idiopathic Pulmonary Fibrosis Clinical Research. Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363:620-628.
30. Yorke J, Jones PW, Swigris JJ. Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax 2010; 65:921-926.
31. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012; 67:804-810.
32. Patel AS, Siegert RJ, Keir GJ, et al. The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respir Med 2013; 107:1438-1443.
33. Swigris JJ, Wilson SR, Green KE, et al. Development of the ATAQ-IPF: a tool to assess quality of life in IPF. Health Qual Life Outcomes 2010; 8:77.
34. Yorke J, Spencer LG, Duck A, et al. Cross-Atlantic modification and validation of the A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQIPF-cA). BMJ Open Respir Res 2014; 1:e000024.
35. Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 2010; 36:1067-1072.
36. Mura M, Porretta MA, Bargagli E, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012; 40:101-109.
37. Holland AE, Fiore JF Jr, Bell EC, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology 2014; 19:1215-1221.
38. Eakin EG, Resnikoff PM, Prewitt LM, et al. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998; 113:619-624.
39. Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003; 58:339-343.
40. Key AL, Holt K, Hamilton A, et al. Objective cough frequency in idiopathic pulmonary fibrosis. Cough 2010; 6:4.
41. Lechtzin N, Hilliard ME, Horton MR. Validation of the cough quality-of-life questionnaire in patients with idiopathic pulmonary fibrosis. Chest 2013; 143:1745-1749.
42. National Institute for Health and Care Excellence (NICE). Clinical guideline. Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163). June 2013.
43. College voor Zorgverzekeringen. GVS-rapport pirfenidone (Esbriet1). September 2013.
44. Collard HR, Bradford WZ, Cottin V, et al. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.Eur Respir J2015; 46:243-249.
45. Ley B, Bradford WZ, Vittinghoff E, et al. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016. [Epub ahead of print]
46. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171:1040-1047.
47. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229-2242.
48. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178:948-955.
49. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374:222-228.
50. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:92-99.
51. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377:1760-1769.
52. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365:1079-1087.
53. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158:641-649.
54. Idiopathic Pulmonary Fibrosis Clinical Research. Martinez FJ, de Andrade JA, Anstrom KJ, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2093-2101.
55. Jaeschke R,Singer J,GuyattGH.Measurement of health status.Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10:407-415.
56. O'Brien EC, Durheim MT, Gamerman V, et al. Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res 2016; 3:e000108.
57. Moodley Y, Goh N, Glaspole I, et al. Australian Idiopathic Pulmonary Fibrosis Registry: vital lessons from a national prospective collaborative project. Respirology 2014; 19:1088-1091.
58. Behr J, Hoeper MM, Kreuter M, et al. Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry. BMJ Open Respir Res 2014; 1:e000010.
59. Guenther A; European IPFN. The European IPF Network: towards better care for a dreadful disease. Eur Respir J 2011; 37:747-748.
60. Ryerson CJ, Tan B, Fell CD, et al. The CAnadian REgistry for Pulmonary Fibrosis (CARE-PF): design and rationale of a national pulmonary fibrosis registry. Can Respir J 2015. [Epub ahead of print]
61. Wuyts W, Dahlqvist C, Schlesser M, et al. PROOF-registry: a prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting. Euro Respir J 2014; 44 (Suppl 58).
62. Evangelista T, Hedley V, Atalaia A, et al. The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks. Orphanet J Rare Dis 2016; 11:17.
63. Riley WT, Pilkonis P, Cella D. Application of the National Institutes of Health Patient-reported Outcome Measurement Information System (PROMIS) to mental health research. J Ment Health Policy Econ 2011; 14:201-208.